A group of FK228 derivatives and their preparation methods and applications

By constructing the engineered strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi in the genome of Burkzai, the novel derivative compound of FK228 was successfully obtained, solving the shortcomings in the development of FK228 derivatives in the prior art and achieving high efficiency The anti-tumor activity and low normal cell inhibition have enhanced the application value of FK228 in anti-tumor treatment.

CN115368439BActive Publication Date: 2024-11-15SHANDONG UNIV

Patent Information

Application Number
CN202211122305.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-15
Publication Date
2024-11-15
Estimated Expiration
2042-09-15

AI Technical Summary

Technical Problem

At present, no patent or literature report has been obtained for FK228 new derivatives using combined biosynthesis technology, limiting the potential of FK228 in the development of anti-tumor drugs.

Method used

The engineered strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi was constructed by knocking out the biosynthetic gene cluster of thailandensis E264 in the genome of Burkholderia thailandensis E264, and the novel derivative of FK228 was generated using this strain. Compounds 1 and 2 were isolated and purified by HPLC to prepare compounds with significant anti-tumor activity.

Benefits of technology

The novel derivatives of FK228 compound 1 and 2 were successfully obtained. The inhibitory activity of tumor cells is higher than that of FK228 and the inhibitory effect on normal cells is weak. It has the potential to be used to prepare anti-tumor drugs, enhancing FK228 in anti-tumor treatment. value of application in.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115368439B_ABST
    Figure CN115368439B_ABST
Patent Text Reader

Abstract

The present invention discloses a group of FK228 derivatives, namely, compound 1 named FK228B and compound 2 named FK228C, whose chemical structures are shown in formula (I). The compound is obtained by culturing and liquid fermentation of a Burkholderia mutant strain BurkholderiathailandensisE264Δtdp::R‑tdp‑dep‑M4spi, and is separated from its fermentation broth. The present invention also discloses the use of the FK228 derivative or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug. Experiments have confirmed that the yields of compound 1 and compound 2 produced by the Burkholderia mutant strain reached 985 mg / L and 453 mg / L, respectively; and compound 1 and compound 2 can significantly inhibit the growth of tumor cells, and their inhibitory activity is higher than that of FK228. It is suggested that the compound provided by the present invention is expected to increase its application value in anti-tumor treatment, and provide new alternative compounds for the development and application of new anti-tumor drugs, which has significant economic value and social benefits.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a group of novel derivative compounds 1 and 2 of histone deacetylase inhibitor FK228, as well as strains producing the compounds, preparation methods and applications thereof in the preparation of anti-tumor drugs, belonging to the field of microbial technology and its products and application technology. Background Art

[0002] Histone deacetylase inhibitors (HDACi) exhibit anticancer activity by changing the acetylation status of histones and non-histone proteins to regulate various cellular events, such as cell survival, differentiation and apoptosis in tumor cells. To date, a variety of histone deacetylase inhibitors, including Vorinostat (SAHA), Romidepsin (FK228), Panobinostat (Farydak) and Belinostat (PXD101), have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer. In addition, there are many other HDAC inhibitors currently in various stages of clinical trials.

[0003] As the only natural and highly selective histone deacetylase inhibitor, FK228 has excellent anti-tumor activity and has been approved by the FDA for the treatment of peripheral and cutaneous T-cell lymphoma. FK228 is synthesized by non-ribosomal peptide synthetase (NRPS) and type I polyketide synthase (PKS). In nature, there are many FK228 compounds, such as Thailandepsin A-F from Burkholderia and Spiruchostatin A-D from Pseudomonas. The biosynthetic gene clusters of these compounds have high homology, and the differences in the chemical structures of these compounds are mainly caused by the diversity of substrate selectivity in their NRPS modules and the different arrangement order of the modules. The identified FK228 biosynthetic gene clusters and homologous gene clusters in the NCBI database provide a material basis for obtaining new compounds of this type through combinatorial biosynthesis.

[0004] At present, using combinatorial biosynthesis to modify biosynthetic pathways at the genetic level, obtaining modified biosynthetic gene clusters to discover new natural products, and screening candidate compounds with greater application value has become a popular means of developing new natural drugs.

[0005] The applicant previously submitted a patent application with application number "2022101093154" entitled "An engineered strain with high yield of FK228 and its construction and application". This patent constructed the chassis bacteria Burkholderia thailandensis E264Δtdp by knocking out the biosynthetic gene cluster tdp of thailandepsin on the genome of Burkholderia thailandensis E264 and adding an attB site in its place, and then integrating the R-tdp-dep hybrid gene cluster into the site, thereby constructing a high-yield FK228 engineered strain Burkholderia thailandensis E264Δtdp::R-tdp-dep, and its FK228 production reached 350 mg / L, which is the highest known production of FK228. However, the search found that there are currently no patents or literature reports on the use of combinatorial biosynthesis technology to transform the gene cluster of FK228 to obtain new FK228 derivatives. Summary of the invention

[0006] In view of the fact that there is currently no combinatorial biosynthesis technology to obtain new FK228 derivatives, the purpose of the present invention is to provide a group of new FK228 derivatives, compounds 1 and 2, as well as strains producing such compounds, preparation methods and their use in the preparation of anti-tumor drugs.

[0007] The present invention discloses a group of FK228 derivatives, characterized in that the FK228 derivatives are polyketide-non-ribosomal polypeptide hybrid compounds, namely, compound 1 named FK228 B and compound 2 named FK228 C, and their chemical structures are shown in formula (I):

[0008]

[0009] The present invention also provides a pharmaceutically acceptable salt, tautomer and stereoisomer of the FK228 derivative.

[0010] The preparation method of the FK228 derivative of the present invention comprises the following steps:

[0011] (1) Using the Burkholderia thailandensis E264Δtdp constructed by knocking out the gene cluster of thailandepsin and adding attB sites at the corresponding positions as the starting strain, the gene cluster R-tdp-dep-M4spi was integrated into the genome of the Burkholderia thailandensis E264Δtdp at the position where thailandepsin was originally expressed by site-specific recombination. The obtained engineered strain was named Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi;

[0012] (2) The second-level seeds of the Burkholderia thailandensis mutant strain E264Δtdp::R-tdp-dep-M4spi were inoculated at a volume ratio of 1-5% into a 250 mL shake flask containing 65 mL of fermentation medium and incubated at 28±1°C and 180±20 r·min -1 The mixture was cultured for 56±2h under the conditions of ; and a fermentation broth containing the FK228 derivative was obtained;

[0013] The primary seed culture method of the Burkholderia mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi is as follows: a ring of the prepared Burkholderia mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi seeds is picked up with an inoculation loop and streaked onto a solid LB culture medium, and cultured in a constant temperature incubator at 37±1°C for 12±2h; the secondary seed culture method is as follows: a cultured primary seed is picked up with an inoculation loop, inoculated into a 250mL shake flask containing 50mL of liquid LB culture medium, and cultured at 37±1°C and 180±20r·min -1 Culture under the same conditions for 18 ± 2 h;

[0014] (3) extracting the fermentation broth with an equal volume of ethyl acetate, repeating 3±1 times, combining the extracts, concentrating and drying under low pressure to obtain a crude extract of the FK228 derivative;

[0015] (4) The crude extract was separated and purified by HPLC: ultrapure water was used as mobile phase A, chromatographic grade acetonitrile was used as mobile phase B, and the gradient elution conditions were 0-5 min 5% B, 5-60 min 40% B, 3 mL / min. The fractions were collected and concentrated and dried under low pressure to obtain pure FK228 derivatives, i.e., compound 1 and compound 2 having the chemical structure shown in formula (I).

[0016] In the preparation method of the above-mentioned FK228 derivative, the construction method of the Burkholderia mutant strain Burkholderiathailandensis E264Δtdp::R-tdp-dep-M4spi is specifically as follows:

[0017] (1) Chemically synthesize the spiDE1 (module 4) gene with the sequence shown in GenBank No. JQ045344.1;

[0018] (2) Using the pR6K-kan-ccdB plasmid as a template, the kan-ccdB gene fragment was obtained by PCR technology;

[0019] (3) Using the engineered strain E. coli GBred-gyrA462, the kan-ccdB fragment was integrated into the p15A-cm-R-tdp-dep plasmid by linear-loop recombination to construct the plasmid p15A-cm-R-tdp-dep-kan-ccdB;

[0020] (4) HindIII endonuclease cleaved p15A-cm-R-tdp-dep-kan-ccdB to obtain the linear fragment p15A-cm-R-tdp-dep;

[0021] (5) The linear fragment p15A-cm-R-tdp-dep and spiDE1 (module 4) gene were assembled into plasmid p15A-cm-R-tdp-dep-M4spi by linear recombination using the engineered strain E. coli GB05-dir;

[0022] (6) Using the engineered strain E. coli GB08-red, the cm resistance gene in the plasmid p15A-cm-R-tdp-dep-M4spi was replaced with the site-specific recombination element kan-oriT-phiC31 by linear-loop recombination to obtain the plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi;

[0023] (7) The plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi was integrated into the genome of the bottom bacteria Burkholderia thailandensis E264Δtdp by site-specific recombination to obtain the engineered strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi.

[0024] In the preparation method of the above FK228 derivative, the formula of the fermentation medium is: glucose 10g·L-1 , tryptone 1.67 g·L -1 , K2HPO4·3H2O 9.17g·L -1 , KH2PO4 2g·L -1 , sodium citrate 0.5 g·L -1 , MgSO4·7H2O 0.1g·L -1 , pH 7.0.

[0025] The invention provides an engineering strain for preparing the above-mentioned FK228 derivative, characterized in that: the engineering strain is named as Burkholderia thailandensis mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi, and its genotype is: Burkholderia thailandensis E264Δtdp, kanamycin resistance gene, tdpR, tdpA, tdpB, tdpC1, tdp-spiDE1(M4spi)-depDE, tdpF, tdpG, tdpH, tdpI and tdpJ, and is constructed by using the complete gene cluster of thailandepsin knocked out and attB site added at the corresponding position to construct the chassis bacterium Burkholderia thailandensis E264Δtdp as the starting strain, and integrating the gene cluster R-tdp-dep-M4spi into the chassis bacterium Burkholderia thailandensis through site-specific recombination. E264Δtdp was originally obtained from the genome at the location where Thailandepsin was expressed.

[0026] The invention relates to the use of the FK228 derivative or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug.

[0027] The experiment confirmed that the FK228 derivative compound 1 (named FK228 B) and compound 2 (named FK228 C) have significant inhibitory activity against four tumor cell lines, which is comparable to doxorubicin and stronger than the inhibitory effect of FK228. At the same time, the inhibitory effect of compound 1 and compound 2 on normal cells is slightly weaker. It has the potential to prepare anti-tumor drugs.

[0028] The present invention further discloses an anti-tumor pharmaceutical preparation containing the FK228 derivative, characterized in that the pharmaceutical preparation contains a therapeutically effective amount of the FK228 derivative compound 1 or compound 2 and one or more pharmaceutically acceptable carrier substances and / or adjuvants.

[0029] The present invention further discloses an anti-tumor drug preparation containing a pharmaceutically acceptable salt, tautomer or stereoisomer of the FK228 derivative, characterized in that the drug preparation contains a therapeutically effective amount of a pharmaceutically acceptable salt, tautomer or stereoisomer of the FK228 derivative and one or more pharmaceutically acceptable carrier substances and / or adjuvants.

[0030] The above-mentioned pharmaceutically acceptable carrier refers to conventional drug carriers in the pharmaceutical field, for example: diluents, excipients such as water, fillers such as starch, sucrose, etc., binders such as cellulose derivatives, alginates, gelatin and polyvinyl pyrrolidone; wetting agents such as glycerol; disintegrants such as agar, calcium carbonate and sodium bicarbonate; absorption accelerators such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; lubricants such as talc, calcium and magnesium stearate, and polyethylene glycol, etc.

[0031] The beneficial effects of the present invention are: for the first time, a group of new derivatives of histone deacetylase inhibitor FK228, compound 1 (named FK228 B) and compound 2 (named FK228 C), as well as the production strains, preparation methods and applications of such compounds in the preparation of anti-tumor drugs are disclosed. Experiments have confirmed that the yields of compound 1 and compound 2 produced by the Burkholderia thailandensis mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi provided by the present invention reached 985 mg / L and 453 mg / L, respectively; compound 1 and compound 2 can significantly inhibit the growth of tumor cells, and their inhibitory activity is higher than that of FK228, indicating that the compounds of the present invention are expected to increase their application value in anti-tumor treatment, and provide new candidate compounds for the development and application of new anti-tumor drugs. The technical solution of the present invention successfully obtains new FK228 derivatives by combining biosynthetic means, which lays a foundation for transforming FK228 to develop higher-value histone deacetylase inhibitor drugs, and has important research and application value for the development of new anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 : Schematic diagram of plasmid p15A-cm-R-tdp-dep-M4spi (A) and plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi (B).

[0033] Figure 2 : The construction process of plasmid p15A-cm-R-tdp-dep-M4spi and plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi.

[0034] Figure 3 : Restriction analysis of plasmid p15A-cm-R-tdp-dep-M4spi and plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi.

[0035] Among them: restriction endonuclease PstI was used to perform restriction analysis on the two plasmids. A represents the restriction gel image of plasmid p15A-cm-R-tdp-dep-M4spi, M represents NEB 1kb marker, C represents the control plasmid p15A-cm-R-tdp-dep, 1-7 and 9-11 pairs of correct recombinants; B represents the restriction gel image of plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi, M represents NEB 1kb marker, 1-7 represents correct recombinants.

[0036] Figure 4 :Yield analysis of compound 1 and compound 2 produced by Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi.

[0037] Figure 5 :Compound 1 1 H NMR (600 MHz) spectrum, the solvent is DMSO-d6.

[0038] Figure 6 :Compound 1 13 C NMR (150 MHz), the solvent was DMSO-d6.

[0039] Figure 7 :Compound 2 1 H NMR (600 MHz) spectrum, the solvent is DMSO-d6.

[0040] Figure 8 :Compound 2 13 C NMR (150 MHz), the solvent was DMSO-d6. DETAILED DESCRIPTION

[0041] The present invention is described in detail below in conjunction with specific drawings and embodiments. The examples described below are only preferred embodiments of the present invention. It should be noted that the following description is only for the purpose of explaining the present invention and does not limit the present invention in any form. Any simple modification, equivalent changes and modifications made to the embodiments according to the technical essence of the present invention are within the scope of the technical solution of the present invention.

[0042] General Notes:

[0043] The recombinase expression strains E. coli GBred-gyrA462, E. coli GB08-red and E. coli GB05-dir involved in the following examples were purchased from Gene Bridges, Germany; E. coli WM3064 and Burkholderia thailandensis E264 were purchased from the German strain storage center DMSZ. The construction of the engineered bacterium Burkholderia thailandensis E264Δtdp is shown in the patent "An engineered strain of high-yield FK228 and its construction and application" previously submitted by the applicant with application number "2022101093154".

[0044] Plasmids pR6K-kan-oriT-phiC31 and pR6K-kan-ccdB were purchased from Gene Bridges, Germany. The construction of plasmid p15A-cm-R-tdp-dep is described in the patent previously submitted by the applicant, "An engineered strain heterologously expressing histone deacetylase inhibitor FK228 and its construction and application" (patent application number: 2021110380454). The spiDE1 (module 4) gene was synthesized by GeneWeiZ.

[0045] LB medium: Tryptone 10 g L -1 , Yeast extract 5g·L -1 , NaCl 10g·L -1 , solid medium plus agar 12g·L -1 ; Fermentation medium: glucose 10g·L -1 , tryptone 1.67 g·L -1 , K2HPO4·3H2O9.17g·L -1 , KH2PO4 2g·L -1 , sodium citrate 0.5 g·L -1 , MgSO4·7H2O 0.1g·L -1 , pH 7.0.

[0046] The spiDE1 (module 4) gene sequence is published in NCBI (GenBank No. JQ045344.1).

[0047] The gene sequencing in the plasmid construction was completed by Sangon Biotech (Shanghai) Co., Ltd. Other plasmids not mentioned are commercially available conventional plasmids, and the method of electroporation into the recipient bacteria is conventional.

[0048] In the following examples, other reagents and consumables involved are all domestically produced.

[0049] Unless otherwise specified, the experimental methods and reagents in the examples are conventional methods and commercially available reagents in the art and can be obtained from commercial channels.

[0050] Example 1: Construction of plasmid p15A-cm-R-tdp-dep-M4spi and plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi

[0051] (1) The specific steps for constructing plasmid p15A-cm-R-tdp-dep-M4spi are as follows:

[0052] First, pR6K-kan-ccdB plasmid was used as template, pkan-ccdB-M4F and pkan-ccdB-M4R were used as primers, kanamycin resistance gene and reverse screening of ccdB gene were obtained by PCR technology, and the purified fragment kan-ccdB was electroporated into E.coli GBred-gyrA462 containing plasmid p15A-cm-R-tdp-dep and induced by 10% L-arabinose. After the cells recovered for 1 hour, they were evenly spread on LB plates containing 15μg / ml kanamycin and placed in a constant temperature incubator at 37°C for overnight culture. Single colonies were picked and digested with restriction endonuclease PstI to obtain plasmid p15A-cm-R-tdp-dep-kan-ccdB. The plasmid p15A-cm-R-tdp-dep-kan-ccdB with the correct sequence was cut with the nuclease HindIII, and the linear vector fragment p15A-cm-R-tdp-dep was obtained after gel recovery; the obtained linear fragment p15A-cm-R-tdp-dep and the synthesized spiDE1 (module 4) gene were co-transformed into E. coli GB05-dir induced by 10% L-arabinose, and after the cells recovered for 1 hour, they were evenly spread on LB plates containing 20μg / ml chloramphenicol, placed in a constant temperature incubator at 37°C, and cultured overnight. A single colony was picked and digested with the restriction endonuclease PstI (for enzyme digestion electrophoresis analysis, see Figure 3 A), a plasmid was obtained and sequenced using primers ck-M4-1 and ck-M4-2, thereby obtaining plasmid p15A-cm-R-tdp-dep-M4spi.

[0053] The primer sequences used for PCR on kan-ccdB are as follows:

[0054] pkan-ccdB-M4F:gcgccggaggcgaacgcgcatgcgctgcccgatgctgtcgttaattaaTATCAACAGGTTGAACTT

[0055] pkan-ccdB-M4R:cgtcgcgttccagtcgtgaatcagccggcgcgcctcgtcttaattaagcTTGCAGTGGGCTTACATG (lowercase letters indicate homology arms).

[0056] The specific steps for PCR amplification of the fragment kan-ccdB using primers pkan-ccdB-M4F and pkan-ccdB-M4R are as follows:

[0057] PCR amplification system:

[0058]

[0059] PCR reaction procedure:

[0060]

[0061]

[0062] The primer sequences used for sequencing the homology arm region are as follows:

[0063] ck-M4-1:GACCTCTATCTGTCGATC

[0064] ck-M4-2:GTAATTCATCGCTTCGTC

[0065] (2) Specific steps for constructing plasmid p15-kan-oriT-phiC31-R-tdp-dep-M4spi:

[0066] First, using pR6K-kan-oriT-phiC31 as a template and oriT-phiC31-kan-1 and oriT-phiC31-kan-2 as primers, the fragment kan-oriT-phiC31 was amplified by PCR, which carried the homologous arms at both ends of the chloramphenicol gene sequence on the p15A-cm-R-tdp-dep-M4spi plasmid. The amplified fragment was recovered and purified by gel recovery.

[0067] The purified fragment kan-oriT-phiC31 was electroporated into E. coli GB08-red containing plasmid p15A-cm-R-tdp-dep-M4spi and induced with 10% L-arabinose. After the cells recovered for 1 hour, they were evenly spread on LB plates containing 15μg / ml kanamycin and placed in a constant temperature incubator at 37°C for overnight culture. Single colonies were picked and digested with restriction endonuclease PstI (see the electrophoresis analysis for enzyme digestion). Figure 3B), screening of the correct recombinant plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi.

[0068] The primer sequences used for PCR on kan-oriT-phiC31 are as follows:

[0069] oriT-phiC31-kan-1: cagatcgcaaaaaacagtacatacagaaggagacatgaacCTTACATGGCGATAGCTAG

[0070] oriT-phiC31-kan-2: gacgtcgatatctggcgaaaatgagacgttgatcggcacgtGATCATATGCGGATTAG (lowercase letters represent homology arms).

[0071] The schematic diagram of the construction process of the above plasmid p15A-cm-R-tdp-dep-M4spi and plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi is shown in Figure 2 .

[0072] Example 2: Construction of Burkholderia thailandensis mutant strain E264Δtdp::R-tdp-dep-M4spi

[0073] The plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi was electroporated into E. coli WM3064 and then conjugated with Burkholderia thailandensis E264Δtdp to finally integrate the gene cluster R-tdp-dep-M4spi into the host chromosome, thus obtaining the Burkholderia thailandensis mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi.

[0074] The conjugation transfer step is as follows: first, the plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi is electroporated into E. coli WM3064, and a single clone is selected for restriction digestion identification to screen the correct clone; E. coli WM3064 containing the plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi is streaked on an LB plate containing 15 μg / ml kanamycin and 1 mM DAP, and inverted and cultured overnight at 37°C; Burkholderia thailandensis E264Δtdp is streaked on an LB plate, and inverted and cultured overnight at 37°C; Burkholderia thailandensis E264Δtdp cultured overnight is selected and cultured on a plate containing 1 mM DAP LB plate, streak an area, and streak E.coli WM3064 containing plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi cultured overnight on it; after 6 hours of culture, wash out the bacterial lawn with LB, take 100ul, and streak on an LB plate containing 300μg / ml kanamycin. Pick a single clone, perform colony PCR, and identify the correct clone, which is the mutant strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi.

[0075] Example 3: Preparation of FK228 derivatives

[0076] Primary seed culture: Pick a ring of the Burkholderia mutant strain Burkholderiathailandensis E264Δtdp::R-tdp-dep-M4spi prepared in Example 2 and streak it on a solid LB medium with an inoculation loop, and culture it in a constant temperature incubator at 37±1°C for 12±2h;

[0077] Secondary seed culture: Use an inoculation loop to pick the cultured primary seeds and inoculate them into a 250 mL shake flask containing 50 mL of liquid LB medium. Incubate at 37 ± 1 °C and 180 ± 20 r / min. -1 Culture under the same conditions for 18 ± 2 h;

[0078] Fermentation culture: Inoculate the secondary seeds at a volume ratio of 1% into a 250 mL shake flask containing 65 mL of fermentation medium and incubate at 28 ± 1 °C and 180 ± 20 r / min. -1 The culture was carried out under the conditions of 56±2h; and a fermentation broth containing FK228 derivatives was obtained.

[0079] The fermentation broth was extracted with an equal volume of ethyl acetate, and the extraction was repeated 3±1 times, and the extracts were combined, concentrated and dried under low pressure to obtain a crude extract of the FK228 derivative;

[0080] HPLC separation and purification was applied: ultrapure water was used as mobile phase A, chromatographic grade acetonitrile was used as mobile phase B, the gradient elution conditions were 0-5 min 5% B, 5-60 min 40% B, 3 mL / min, the fractions were collected, concentrated and dried under low pressure to obtain pure FK228 derivatives, namely compound 1 (named FK228 B) and compound 2 (named FK228 C) with the chemical structure shown in formula (I).

[0081]

[0082] Example 4: Structural Identification of Compound 1 and Compound 2 Represented by Formula (I)

[0083] The structures of compound 1 and compound 2 were analyzed by NMR, high-resolution mass spectrometry, infrared, Marfey's analysis and other data, and the following physical and chemical properties were obtained. The NMR data of compound 1 and compound 2 are shown in Table 1:

[0084] Compound 1: white amorphous powder; ECD(0.21mmol / L,MeOH)λ max (Δε13.8)223nm; UV(MeOH)λ max (logε)205(4.35);IR v max 2925,1745,1659,1517cm -1 ;(+)-HRESIMS m / z 513.1836[M+H] + (calcd for C 22 H 33 N4O6S2,513.1836).

[0085] Compound 2: white amorphous powder; ECD(1.98mmol / L,MeOH)λ max (Δε1.7)228nm; UV(MeOH)λ max (logε)206(3.53);IR v max 2925,1741,1669,1524cm -1 ;(+)-HRESIMS m / z 513.1836[M+H] + (calcd for C 22 H 33 N4O6S2,513.1836).

[0086] Table 1 Compounds 1 and 2 in DMSO-d6 1 H NMR (600 MHz) and 13 C NMR (150 MHz) data

[0087]

[0088] Example 5: Antitumor activity of compound 1 and compound 2 represented by formula (I)

[0089] Internationally used tumor cell lines were used, namely: human lung cancer cells H1299, human breast cancer cells MDA-MB-231, human pancreatic cancer cells mia-paca-2 and human leukemia cells K562. The cytotoxic activity of the compound on human normal liver cells QSG-7701 was also tested. The test method was CCK-8 method.

[0090] Compounds: 10 mM stock solution of compound 1 (named FK228 B) or compound 2 (named FK228 C), aliquoted and stored at -20°C for future use.

[0091] Cells were seeded in 96-well plates at a cell density of 3-4×10 3 / well. Cultured in a cell culture incubator at 5% CO2 and 37°C. After the cells adhered to the wall, the sample to be tested was added at a specified concentration. The negative control group was DMSO at the same concentration, and the positive control was doxorubicin (Adr). Three parallel wells were set for the same concentration of drug. After 48 hours of drug addition, 10 μL CCK8 was added to each well and cultured for another 4 hours. The OD value of each well was detected at 450 nm using an enzyme reader, and the IC 50 IC was calculated using software (Prism 8.0) 50 The experiment was repeated three times. The IC values ​​calculated independently for 3 times 50 Statistics were performed and expressed as mean ± standard deviation (SD).

[0092] Three parallel experiments were performed for each cell line. The experimental results are shown in Table 2:

[0093] Table 2 Inhibitory effects of compounds on tumor cell lines and normal cell lines (IC 50 ,μM)

[0094]

[0095] The experimental results showed that compound 1 (named FK228 B) or compound 2 (named FK228 C) had significant inhibitory activity against the four tumor cell lines, which was comparable to that of doxorubicin and stronger than that of FK228. At the same time, the inhibitory effects of compound 1 and compound 2 on normal cells were slightly weaker.

Claims

1. A method for preparing a group of FK228 derivatives, wherein the FK228 derivatives are polyketide-non-ribosomal polypeptide hybrid compounds, namely compound 1 named FK228 B and compound 2 named FK228 C, the preparation steps are: (1) Using the Burkholderia thailandensis E264Δtdp constructed by knocking out the gene cluster of thailandepsin and adding attB sites at the corresponding positions as the starting strain, the gene cluster R-tdp-dep-M4spi was integrated into the genome of the Burkholderia thailandensis E264Δtdp at the position where thailandepsin was originally expressed by site-specific recombination. The obtained engineered strain was named Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi; in, The engineered strain genotype of the FK228 derivative is: Burkholderia thailandensis E264Δtdp, kanamycin resistance gene, tdpR, tdpA, tdpB, tdpC1, tdp-spiDE1 (M4spi), tdpF, tdpG, tdpH, tdpI and tdpJ. The engineered strain genotype of the FK228 derivative is: Burkholderia thailandensis E264Δtdp, which is constructed by knocking out the complete gene cluster of thailandepsin and adding attB site at the corresponding position as the starting strain, and integrating the gene cluster R-tdp-dep-M4spi into the genome of the position where thailandepsin is originally expressed by the engineered strain Burkholderia thailandensis E264Δtdp through site-specific recombination. The specific construction method is: 1) Chemically synthesize the gene sequence of the spiDE1 gene shown in GenBank No. JQ045344.1, which is Module 4 in the spi gene cluster and is named M4spi; 2) Using the pR6K-kan-ccdB plasmid as a template, the kan-ccdB gene fragment was obtained by PCR technology; 3) Using the engineered strain E. coli GBred-gyrA462, the kan-ccdB fragment was integrated into the p15A-cm-R-tdp-dep plasmid by linear-loop recombination to construct the plasmid p15A-cm-R-tdp-dep-kan-ccdB; 4) HindIII endonuclease cleaves p15A-cm-R-tdp-dep-kan-ccdB to obtain the linear fragment p15A-cm-R-tdp-dep; 5) The linear fragment p15A-cm-R-tdp-dep and spiDE1 gene were assembled into plasmid p15A-cm-R-tdp-dep-M4spi by linear recombination using the engineered strain E. coli GB05-dir; 6) Using the engineered strain E. coli GB08-red, the cm resistance gene in the plasmid p15A-cm-R-tdp-dep-M4spi was replaced with the site-specific recombination element kan-oriT-phiC31 by linear-loop recombination to obtain the plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi; 7) Integrate the plasmid p15A-kan-oriT-phiC31-R-tdp-dep-M4spi into the genome of Burkholderia thailandensis E264Δtdp by site-specific recombination to obtain the engineered strain Burkholderia thailandensis E264Δtdp::R-tdp-dep-M4spi; (2) The second-level seeds of the Burkholderia thailandensis mutant strain E264Δtdp::R-tdp-dep-M4spi were inoculated at a volume ratio of 1-5% into a 250 mL shake flask containing 65 mL of fermentation medium and incubated at 28±1°C and 180±20 r·min -1 The mixture was cultured for 56±2h under the conditions of ; and a fermentation broth containing the FK228 derivative was obtained; The formula of the fermentation medium is: glucose 10g·L -1 , tryptone 1.67 g·L -1 , K 2 HPO 4 ·3H 2 0.917g·L -1 , KH 2 PO 4 2g·L -1 , sodium citrate 0.5 g·L -1 , MgSO 4 7H 2 O 0.1g·L -1 , pH 7.0; (3) extracting the fermentation broth with an equal volume of ethyl acetate, repeating 3±1 times, combining the extracts, concentrating and drying under low pressure to obtain a crude extract of the FK228 derivative; (4) Separating and purifying the crude extract by HPLC: using ultrapure water as mobile phase A and chromatographically pure acetonitrile as mobile phase B, with gradient elution conditions of 0-5 min 5% B, 5-60 min 40% B, 3 mL / min, collecting fractions, concentrating and drying at low pressure to obtain pure FK228 derivatives, namely, compound 1 of FK228 B and compound 2 of FK228 C having the chemical structure shown in formula (I);

Citation Information

Patent Citations

  • Engineering strain with high yield of FK228 as well as construction and application of engineering strain

    CN114410560A

  • Sequences for FK228 biosynthesis and methods of synthesizing FK228 and FK228 analogs

    US20100261878A1

Cited By

  • Novel tumor microenvironment immunomodulator and application thereof

    CN119733056A

  • Compound FK228D as well as preparation method and application thereof

    CN122080120A